(Q37000780)

17 August 2017

1 reference

title

Glitazones in the treatment of cardiovascular risk factors (English)

1 reference

17 August 2017

author name string

Mohamed Amine Bouhlel

series ordinal

1

1 reference

17 August 2017

Giulia Chinetti-Gbaguidi

series ordinal

2

1 reference

17 August 2017

Bart Staels

series ordinal

3

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Fundamental and Clinical Pharmacology

17 August 2017

published in

1 reference

17 August 2017

volume

21 Suppl 2

1 reference

17 August 2017

page(s)

7-13

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

17 August 2017

1 reference

Atherosclerosis and extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

The role of PPARs in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Molecular determinants of nuclear receptor-corepressor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Phosphorylation of PPARs: from molecular characterization to physiological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Caveolins and macrophage lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARgamma ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Activation of peroxisome proliferator-activated receptor gamma and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

IL-6 switches the differentiation of monocytes from dendritic cells to macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Peroxisome proliferator-activated receptors in inflammation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2007.00531.X

10.1111/J.1472-8206.2007.00531.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference